31.7 C
New York
Sunday, June 14, 2026

Tag: dna

newssourceFORcompanyinformationcontent1marketreleases

Nature Medicine Published Phase 1 Results of Innovent Biologics’ Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics’ EsoGuard® Esophageal DNA Test

Virtual public CAC meeting to be held September 4, 2025, at 2:00 p.m. ET NEW YORK, July 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid"...

The 2025 Mammoth International Contest on Omics Sciences – Young Scientists Track Now Open for Hot Registration!

SHENZHEN, China, July 16, 2025 /PRNewswire/ -- Under the guidance of UNESCO and the United Nations International Cooperation Public Welfare Organization, the 2025 Mammoth...

Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors

TAIPEI and SAN DIEGO, July 15, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for...

RESEARCH SHOWS EARLY CANCER CELLS CAN BE RAPIDLY DETECTED THROUGH ELECTRONIC SEMICONDUCTORS

CLEVELAND, July 15, 2025 /PRNewswire/ -- IdentifySensors Biologics, a leader in digital diagnostic technologies, has demonstrated that its electronic biosensors used to detect pathogens...

Rakovina Therapeutics Congratulates Partner – Variational AI for Winning LifeSciencesBC’s 2025 Emerging Biotech Company of the Year Award

Award Recognition underscores the importance of AI-driven drug discovery 
Award Recognition underscores the importance of AI-driven drug discovery

DexLab Doubles Down On Its Fresh Division – CaLab, To Deploy Its Technical Expertise In The Asia-Pacific Battlefield

SINGAPORE, July 11, 2025 (GLOBE NEWSWIRE) -- DexLab, the leading Solana-native token launching & tooling platform, today announced the launch of its fully independent Asia-Pacific subsidiary CaLab. Built on DexLab's battle-tested technical infrastructure, CaLab will operate as a regional powerhouse focused on serving APAC markets while maintaining technological interoperability with its parent platform.

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline...

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline...

Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025

SAN DIEGO, July 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2025 following...

SunsolveMD by TheSolveMD and Elsa Hosk Redefine Sun Protection with In-House Biotech Innovation

LONDON and LOS ANGELES and COPENHAGEN, Denmark, July 10, 2025 /PRNewswire/ -- SunsolveMD by TheSolveMD, the skin health brand pioneering the future of SPF,...

Vitaquest Names Plant-based Proteins, Nootropics Among Top 2026 Supplement Trends

Plant-based proteins, nootropics among Top 2026 Dietary Supplement Trends in newly released Vitaquest report.

Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic

CAMBRIDGE, United Kingdom and MONTREAL, July 10, 2025 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the formation of its dedicated clinical team and the expansion of its research team. These developments represent a significant milestone in the company’s ongoing progress in advancing its RNA-based immunotherapies, known as CryptiVax™, into clinical trials.

BCC Research Releases 2024 Protein Synthesis Research Review

"Driving Innovation and Sustainability: The Vital Role of Protein Synthesis in Modern Biotechnology and Its Impact on Chronic Disease Treatment, Technological Advances, and Market...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDna

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers